Colistin enhances therapeutic efficacy of daptomycin or teicoplanin in a murine model of multiresistant Acinetobacter baumannii sepsis

Diagn Microbiol Infect Dis. 2016 Dec;86(4):392-398. doi: 10.1016/j.diagmicrobio.2016.09.010. Epub 2016 Sep 17.

Abstract

We investigated the efficacy of colistin combined with teicoplanin or daptomycin in an experimental mouse model of multiresistant Acinetobacter baumannii infection. Animal received intraperitoneally 1ml saline containing 2×1010CFU of A. baumannii. Colistin, daptomycin, teicoplanin, and colistin plus daptomycin or teicoplanin were given by intraperitoneal administration 2h after bacterial challenge. A control group received sodium chloride solution. In the in vitro study A. baumannii showed to be susceptible only to colistin with MIC of 2mg/l. In the in vivo study, colistin alone showed a good antimicrobial efficacy. When combined with teicoplanin or daptomycin, colistin produced the lowest bacterial and the best survival rates. In immunological studies, when colistin was associated to daptomycin or teicoplanin, both the number and the cytotoxic activity of NK cells increased. In conclusion, colistin combined with teicoplanin or daptomycin may improve the therapy of multiresistant A. baumannii infection.

Keywords: A. baumannii; Animal model; Multiresistant organisms; Sepsis; Synergy.

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter Infections / microbiology
  • Acinetobacter baumannii / drug effects*
  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Colistin / therapeutic use*
  • Daptomycin / therapeutic use*
  • Disease Models, Animal
  • Drug Resistance, Multiple, Bacterial*
  • Drug Synergism
  • Drug Therapy, Combination
  • Male
  • Mice, Inbred BALB C
  • Microbial Sensitivity Tests
  • Sepsis / drug therapy*
  • Sepsis / microbiology
  • Survival Analysis
  • Teicoplanin / therapeutic use*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Teicoplanin
  • Daptomycin
  • Colistin